New pill could tame involuntary twitching in mental health patients
NCT ID NCT07365462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug, NBI-1065890, to see if it can reduce involuntary movements in adults with tardive dyskinesia, a condition often caused by long-term use of certain mental health medications. About 100 participants with schizophrenia, bipolar disorder, or depression will receive either the drug or a placebo for 8 weeks. The main goal is to measure changes in movement severity using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-1065890
What this could lead to
If it works, this could provide a new option to reduce uncontrolled movements in people with tardive dyskinesia.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGBryant, Arkansas, 72022, United States
-
Neurocrine Clinical Site
RECRUITINGChino, California, 91710, United States
-
Neurocrine Clinical Site
RECRUITINGFountain Valley, California, 92708, United States
-
Neurocrine Clinical Site
RECRUITINGHuntington Beach, California, 92648, United States
-
Neurocrine Clinical Site
RECRUITINGLong Beach, California, 90807, United States
-
Neurocrine Clinical Site
RECRUITINGTemecula, California, 92591, United States
-
Neurocrine Clinical Site
RECRUITINGTorrance, California, 90501, United States
-
Neurocrine Clinical Site
RECRUITINGBoca Raton, Florida, 33486, United States
-
Neurocrine Clinical Site
RECRUITINGBonita Springs, Florida, 34134, United States
-
Neurocrine Clinical Site
RECRUITINGHialeah, Florida, 33012, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33176, United States
-
Neurocrine Clinical Site
RECRUITINGOrange City, Florida, 32763, United States
-
Neurocrine Clinical Site
RECRUITINGTampa, Florida, 33629, United States
-
Neurocrine Clinical Site
RECRUITINGMarietta, Georgia, 30060, United States
-
Neurocrine Clinical Site
RECRUITINGLincoln, Nebraska, 68526, United States
-
Neurocrine Clinical Site
RECRUITINGBeachwood, Ohio, 44122, United States
-
Neurocrine Clinical Site
RECRUITINGFort Worth, Texas, 76104, United States
-
Neurocrine Clinical Site
RECRUITINGHouston, Texas, 77030, United States